Name: A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization (Video) | JoVE Journal
Uploaded: 2023-01-20T12:40:00.000+00:00
Duration: 2 min 46 s
Description: Learn nasal nebulization of bleomycin to induce pulmonary fibrosis in mice with uniform drug distribution. This method enables study of disease mechanisms and therapeutic development.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the National Natural Science Foundation of China (No. 92068108).

The Animal Studies Committee of the China-Japan Friendship Hospital (Beijing, China) approved all of the procedures involving mice that were performed as part of this study (NO.190108). Mice were kept in the sterile animal room of the China-Japan Friendship Clinical Medical Research Institute, with a room temperature of 20-25 &#176;C, relative humidity of 40%-70%, animal light intensity of 15-20 LX, and alternating light and dark for 12 h/12 h. Animals had free access to food and water.
1. Mice
<ol>
	<li>Ensure that all animals are acclimated to the housing facility for 7 days before nebulization.</li>
	<li>Use male C57BL/6 mice, aged 8-10 weeks, for nebulization.</li>
</ol>
2. Nasal bleomycin nebulization
<ol>
	<li>Bleomycin preparation 
	CAUTION: BLM is a chemical poison, which kills tumors but may also damage normal cells and normal tissues.
	<ol>
		<li>Prepare BLM solution at a clean bench.
		<ol>
			<li>To obtain the working concentration (7 U/mL), resuspend 15 U of BLM hydrochloride in 2.14 mL of normal saline. Carefully mix the resuspended BLM until it is completely dissolved.</li>
		</ol>
		</li>
		<li>Store the working solution at 4 &#176;C or on ice and use within 1 day. Before nebulization, bring the BLM solution to room temperature.</li>
	</ol>
	</li>
	<li>Anesthesia
	<ol>
		<li>Prepare for anesthesia by dissolving 0.1 g of pentobarbital sodium in 10 mL of normal saline. Store the working anesthesia solution in a dark place at 4 &#176;C and use within 3 days.</li>
		<li>Anesthetize the mice by injecting the pentobarbital sodium into the abdomen, using a 1 mL syringe with a 26 G needle, at a final dose of 75 mg/kg body weight. 
		NOTE: In this study, the mice did not respond to this dose for at least 30 min. If necessary, adjust the dose in consultation with the vet according to the mouse&#39;s response.</li>
		<li>After a few minutes, press the anesthetized mouse&#39;s toes with the index finger and thumb to ensure that the limb withdrawal reflex has disappeared.</li>
	</ol>
	</li>
	<li>Preparation of the nebulization system
	<ol>
		<li>After calibrating the instrument, secure the anesthetized mouse with a soft mesh cover (Figure 1A), add the working BLM solution to the top atomizing head of the exposure tower with a pipette (Figure 1B), and run the nebulizer for 30 min to achieve stable atomization. 
		NOTE: The workflow is shown in Figure 1C,D. For detailed operation steps of the software, refer to Supplemental Figure S1 and Supplemental Figure S2, which illustrate steps 2.3.1.1-2.3.1.9.
		<ol>
			<li>Double-click on the flexiWare 8 icon (Supplemental Figure S1A), click on experimentation session (Supplemental Figure S1B), and click on the New Study button (Supplemental Figure S1C).</li>
			<li>Edit the experiment name (Supplemental Figure S1D) and edit the Title and Owner (Supplemental Figure S1E).</li>
			<li>Choose the IX-4DIO template (Supplemental Figure S1F), input the operator (Supplemental Figure S1G), click on the Confirm button (Supplemental Figure S1H) | Next button (Supplemental Figure S1I).</li>
			<li>Choose the Pump and click on next (Supplemental Figure S1J) | Next button (Supplemental Figure S2A) | Next button (Supplemental Figure S2B) | Finish button (Supplemental Figure S2C).</li>
			<li>Click on the Settings for Continuous-1Lmin (three dots, Supplemental Figure S2D) | DIO1, set the Duty Cycle (%) to 25%, and then click OK (Supplemental Figure S2E).</li>
			<li>Click DIO2, set the Duty Cycle (%) to 25%, and then click OK (Supplemental Figure S2F).</li>
			<li>Click DIO3, set the Duty Cycle (%) to 25%, and then click OK (Supplemental Figure S2G).</li>
			<li>Click DIO4, set the Duty Cycle (%) to 25%, and then click OK (Supplemental Figure S2H).</li>
			<li>Click the top green button (left) to start operating, and click the red button (right) to stop work. Click the x at the top-right corner to quit (Supplemental Figure S2I).</li>
		</ol>
		</li>
		<li>In the BLM group, atomize 12 mice at a time, for four times in total, up to a total of 48 mice. Atomize six mice at a time in the normal control group with normal saline.</li>
	</ol>
	</li>
	<li>Animal recovery
	<ol>
		<li>After treatment in the nebulizer for 30 min, move the mouse to a recovery cage equipped with a heating pad.</li>
		<li>Observe the mice until they are fully conscious.</li>
		<li>Once the mouse is confirmed to be in good condition, which means that it can move freely, return it to its original cage. Do not place it with other animals until it has completely recovered.</li>
		<li>Check physiological indexes, including breathing rate, survival, and any symptoms, twice during the 24 h following treatment with BLM.</li>
	</ol>
	</li>
</ol>
3. Lung tissue processing
<ol>
	<li>At 9, 16, and 23&#160;days after BLM administration, sacrifice six mice by injecting them in the abdomen with pentobarbital sodium (final dose 100 mg/kg body weight).</li>
	<li>Remove the trachea and lungs and immediately rinse with cold phosphate-buffered saline.</li>
	<li>Fix the left lung in 10% neutral formalin buffer for 24 h before paraffin embedding.</li>
	<li>Hematoxylin-eosin staining (H&#38;E staining)
	<ol>
		<li>Dehydrate the fixed lung tissue in a dehydrator.</li>
		<li>Place the dehydrated lung tissue block in a wax-dissolving box at 56 &#176;C for 1 h.</li>
		<li>For embedding, pour the melted paraffin into the mold box, and then quickly place the paraffin-impregnated tissue block at the bottom of the mold box, cool, and solidify.</li>
		<li>Fix the embedded wax block on the microtome, adjust the slicing table up and down to an appropriate position, push the blade, adjust the scale, and cut a slice with a thickness of 4 &#181;m. Use tweezers to place the slice in a display box filled with water to uncurl (front side up).</li>
		<li>Patch and bake the slices. After the wax slice has completely uncurled, place the glass slide against the wax slice at a 135&#176; angle, use tweezers to move the wax slice onto the glass slide, lift the glass slide, and adjust the position of the wax slice as needed. Place the slides with mounted wax slices on a constant-temperature table at 47 &#176;C for 1 min to again allow the slices to uncurl; once the slices are completely flat, place the slides in a 62 &#176;C incubator for 1 h.</li>
		<li>For dewaxing, place the baked slides in xylene for 20 min twice.</li>
		<li>For rehydration, place the slides in a graded alcohol series to rehydrate the lung tissue slices: 100% alcohol for 2 min, 95% alcohol for 1 min, 90% alcohol for 1 min, 85% alcohol for 1 min, 75% alcohol for 1 min, and distilled water for 3&#160;min.</li>
		<li>Stain the sections in hematoxylin for 5 min. Wash for 1 min twice, then place in a 0.5% hydrochloric acid alcohol differentiation solution for 5 s, wash with water for 1 min twice, place in Blue staining solution for 8-10 s, rinse twice with tap water, and stain with eosin for 30 s.</li>
		<li>For dehydration and destaining, place the stained sections in 75% alcohol for 1 min, 85% alcohol for 1 min, 90% alcohol for 1 min, 95% alcohol for 1 min, 100% alcohol for 1 min, and then xylene for 1 min twice, and remove all remaining liquid with absorbent paper.</li>
		<li>For mounting, pace a drop of neutral gum sealing solution in the middle of the slice and mount a coverslip.</li>
	</ol>
	</li>
	<li>Morphological grading standard of mouse lung tissue
	<ol>
		<li>Using the method described by Ashcroft et al., have an investigator blinded to the experimental group randomly select three microscopic fields from each sample, and observe the degree of pulmonary fibrosis at 100x magnification: grade 0, normal lung; grade 1, slightly swollen alveoli, localized mild fibrosis; grade 2, marked fibrosis (thickness of alveolar wall greater than three times normal), with fibrous foci; grade 3, continuous areas of fibrosis (thickness of alveolar wall three times greater than normal); grade 4, fusion of fibrous foci, with the fibrotic area accounting for less than 10% of the lung tissue; grade 5, the fibrous foci are fused, the fibrosis area is 10% to 50%, and the alveolar structure is significantly damaged; grade 6, large continuous fibrous foci (greater than 50% of the lung tissue); grade 7, the alveolar space is filled with fibrous tissue, pulmonary bullae are present; grade 8, complete fibrosis.</li>
		<li>Assign a score corresponding to the grade to each field of view (e.g., grade 4 equals four points), and score each group of six samples separately.</li>
	</ol>
	</li>
</ol>

<ol><li>Raghu, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diagnosis+of+idiopathic+pulmonary+fibrosis.+An+official+ATS%2FERS%2FJRS%2FALAT+clinical+practice+guideline%5BTitle%5D)+AND+%22American+Journal+of+Respiratory+and+Critical+Care+Medicine%22%5BJournal%5D)">Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline.</a> American Journal of Respiratory and Critical Care Medicine. 198 (5), e44-e68 (2018).</li>
<li>Moore, B. B., Hogaboam, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Murine+models+of+pulmonary+fibrosis%5BTitle%5D)+AND+%22American+Journal+of+Physiology.+Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Murine models of pulmonary fibrosis.</a> American Journal of Physiology. Lung Cellular and Molecular Physiology. 294 (2), L152-L160 (2008).</li>
<li>Degryse, A. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Repetitive+intratracheal+bleomycin+models+several+features+of+idiopathic+pulmonary+fibrosis%5BTitle%5D)+AND+%22American+Journal+of+Physiology-Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis.</a> American Journal of Physiology-Lung Cellular and Molecular Physiology. 299 (4), L442-L452 (2010).</li>
<li>Sueblinvong, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Predisposition+for+disrepair+in+the+aged+lung%5BTitle%5D)+AND+%22The+American+Journal+of+the+Medical+Sciences%22%5BJournal%5D)">Predisposition for disrepair in the aged lung.</a> The American Journal of the Medical Sciences. 344 (1), 41-51 (2012).</li>
<li>Peng, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bleomycin+induces+molecular+changes+directly+relevant+to+idiopathic+pulmonary+fibrosis%3A+a+model+for+%26%2334%3Bactive%26%2334%3B+disease%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for &#34;active&#34; disease.</a> PLoS One. 8 (4), e59348(2013).</li>
<li>Izbicki, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Time+course+of+bleomycin-induced+lung+fibrosis%5BTitle%5D)+AND+%22International+Journal+of+Experimental+Pathology%22%5BJournal%5D)">Time course of bleomycin-induced lung fibrosis.</a> International Journal of Experimental Pathology. 83 (3), 111-119 (2002).</li>
<li>Aguilar, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bone+marrow+stem+cells+expressing+keratinocyte+growth+factor+via+an+inducible+lentivirus+protects+against+bleomycin-induced+pulmonary+fibrosis%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis.</a> PLoS One. 4 (11), e8013(2009).</li>
<li>Ortiz, L. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mesenchymal+stem+cell+engraftment+in+lung+is+enhanced+in+response+to+bleomycin+exposure+and+ameliorates+its+fibrotic+effects%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences%22%5BJournal%5D)">Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.</a> Proceedings of the National Academy of Sciences. 100 (14), 8407-8411 (2003).</li>
<li>Rojas, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bone+marrow-derived+mesenchymal+stem+cells+in+repair+of+the+injured+lung%5BTitle%5D)+AND+%22American+Journal+of+Respiratory+Cell+and+Molecular+Biology%22%5BJournal%5D)">Bone marrow-derived mesenchymal stem cells in repair of the injured lung.</a> American Journal of Respiratory Cell and Molecular Biology. 33 (2), 145-152 (2005).</li>
<li>Ortiz, L. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Interleukin+1+receptor+antagonist+mediates+the+antiinflammatory+and+antifibrotic+effect+of+mesenchymal+stem+cells+during+lung+injury%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences%22%5BJournal%5D)">Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.</a> Proceedings of the National Academy of Sciences. 104 (26), 11002-11007 (2007).</li>
<li>Foskett, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Phase-directed+therapy%3A+TSG-6+targeted+to+early+inflammation+improves+bleomycin-injured+lungs%5BTitle%5D)+AND+%22American+Journal+of+Physiology-Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs.</a> American Journal of Physiology-Lung Cellular and Molecular Physiology. 306 (2), L120-L131 (2014).</li>
<li>Hecker, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reversal+of+persistent+fibrosis+in+aging+by+targeting+Nox4-Nrf2+redox+imbalance%5BTitle%5D)+AND+%22Science+Translational+Medicine%22%5BJournal%5D)">Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance.</a> Science Translational Medicine. 6 (231), 231ra47(2014).</li>
<li>Taooka, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effects+of+neutrophil+elastase+inhibitor+on+bleomycin-induced+pulmonary+fibrosis+in+mice%5BTitle%5D)+AND+%22American+Journal+of+Respiratory+%26+Critical+Care+Medicine%22%5BJournal%5D)">Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice.</a> American Journal of Respiratory & Critical Care Medicine. 156 (1), 260-265 (1997).</li>
<li>Gharaee-Kermani, M., Ullenbruch, M., Phan, S. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Animal+models+of+pulmonary+fibrosis%5BTitle%5D)+AND+%22Methods+in+Molecular+Medicine%22%5BJournal%5D)">Animal models of pulmonary fibrosis.</a> Methods in Molecular Medicine. , 251-259 (2005).</li>
<li>Orlando, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+mouse+lung+injury+by+endotracheal+injection+of+bleomycin%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Induction of mouse lung injury by endotracheal injection of bleomycin.</a> Journal of Visualized Experiments. (146), e58902(2019).</li>
<li>Moore, B. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Animal+models+of+fibrotic+lung+disease%5BTitle%5D)+AND+%22American+Journal+of+Respiratory+Cell+and+Molecular+Biology%22%5BJournal%5D)">Animal models of fibrotic lung disease.</a> American Journal of Respiratory Cell and Molecular Biology. 49 (2), 167-179 (2013).</li>
<li>Gauldie, J., Kolb, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Animal+models+of+pulmonary+fibrosis%3A+how+far+from+effective+reality%5BTitle%5D)+AND+%22American+Journal+of+Physiology-Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Animal models of pulmonary fibrosis: how far from effective reality.</a> American Journal of Physiology-Lung Cellular and Molecular Physiology. 294 (2), L151(2008).</li>
<li>Jenkins, R. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+official+American+thoracic+society+workshop+report%3A+use+of+animal+models+for+the+preclinical+assessment+of+potential+therapies+for+pulmonary+fibrosis%5BTitle%5D)+AND+%22American+Journal+of+Respiratory+Cell+and+Molecular+Biology%22%5BJournal%5D)">An official American thoracic society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis.</a> American Journal of Respiratory Cell and Molecular Biology. 56 (5), 667-679 (2017).</li>
<li>Moeller, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+bleomycin+animal+model%3A+A+useful+tool+to+investigate+treatment+options+for+idiopathic+pulmonary+fibrosis%5BTitle%5D)+AND+%22The+International+Journal+of+Biochemistry+%26+Cell+Biology%22%5BJournal%5D)">The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis.</a> The International Journal of Biochemistry & Cell Biology. 40 (3), 362-382 (2008).</li>
</ol>

The authors have no conflicts of interest to disclose.

Intratracheal injection of bleomycin results in an acute inflammatory and fibrotic response in both lungs and can be considered an effective approach to establish an experimental mouse model of human interstitial lung disease. Intratracheal administration is the most commonly used route of administration2,3,4,5,6,7,</sup...

Pulmonary fibrosis is a progressive disease process in which excessive deposition of extracellular matrix components, primarily type I collagen, in the interstitium of the lungs leads to impaired lung function1. The pathophysiology of pulmonary fibrosis is complex, and treatment options are currently quite limited. Mouse models remain an important tool to study the pathogenic mechanisms that contribute to the emergence and progression of the disease, as well as new strategies for drug development.
A variety of animal models of pulmonary fibrosis rely on intratracheal instillation of BLM2,3,4,5,6,7,8,9,10,11,12. However, the distribution of fibrotic changes that BLM causes in the lungs is not uniform, and the animals are at risk of asphyxiation during the instillation process. Although intraperitoneal injection of BLM induces relatively uniform fibrotic changes in the lung, it requires multiple doses because of insufficient drug targeting. Intratracheal aerosol administration via a laryngoscope does not require tracheotomy or puncture, and the resulting drug distribution within the lung is optimal. However, the aerosolized particles are large (5-40 &#181;m), and thus cannot reach the subpleural area of the lung tissue.
In this study, intrapulmonary administration of BLM is carried out by nasal nebulization. During nebulization, the mice breathed spontaneously and inhaled the drug particles. The aerosolized particles were 2.5-4 &#181;m in size, which enabled them not only to distribute evenly throughout the lung but also to reach the subpleural area. Under low magnification, the most significant lung histopathological features of patients with idiopathic pulmonary fibrosis (IPF) are the varying severity of lesions, inconsistent distribution, alternating distribution of different phase lesions, and the presence of interstitial inflammation, fibrotic lesions, and honeycomb lung changes, alternating with normal lung tissue. These pathological changes predominantly involve the peripheral subpleural parenchyma or lobular septum around the bronchioli. Thus, given that this approach enables BLM particles to reach the subpleural area of the lungs, this model closely simulates the clinical characteristics of the disease in humans.

<table><tbody><tr><td>&amp;nbsp;bleomycin</td><td>Bioway/Nippon Kayaku Co Ltd</td><td>&amp;nbsp;DP721</td><td>Fibrosis model drugs</td></tr><tr><td>0.9% saline for injection</td><td>Baxter Healthcare(Tianjin)Co.,Ltd.</td><td></td><td>Bleomycin preparation</td></tr><tr><td>1 mL syringe</td><td>BD</td><td>300481</td><td>Anesthetize animals</td></tr><tr><td>10% neutral formalin buffer</td><td>TechaLab Biotech Company</td><td></td><td>Fix lung tissue</td></tr><tr><td>15 mL centrifuge tube</td><td>corning</td><td>430790</td><td>Prepare for anesthesia</td></tr><tr><td>20 &amp;deg;C refrigerator</td><td>New-fly group</td><td>BCD-213K</td><td>Store drugs</td></tr><tr><td>4 &amp;deg;C refrigerator</td><td>New-fly group</td><td>BCD-213K</td><td>Store drugs</td></tr><tr><td>Adobe illustrator cc2020</td><td>Adobe</td><td></td><td>Process images</td></tr><tr><td>blue back liquid</td><td>Beijing Chemical Works</td><td></td><td>tissue staining</td></tr><tr><td>clean bench</td><td>Suzhou Sujie Purifying Equipment Co.,Ltd.</td><td></td><td>Bleomycin preparation</td></tr><tr><td>differentiation fluid</td><td>Beijing Chemical Works</td><td></td><td>tissue staining</td></tr><tr><td>Electronic balance</td><td>METTLER TOLEDO</td><td>AA-160</td><td>Prepare for anesthesia</td></tr><tr><td>eosin stain</td><td>Beijing Yili Fine Chemicals Co,Ltd.</td><td></td><td>tissue staining</td></tr><tr><td>Heating pad</td><td>HIDOM</td><td></td><td>Mice incubation</td></tr><tr><td>hematoxylin stain</td><td>Beijing Yili Fine Chemicals Co,Ltd.</td><td></td><td>tissue staining</td></tr><tr><td>phosphate buffered saline (PBS) buffer</td><td>Hyclone</td><td>SH30256.01</td><td>Clean lung tissue</td></tr><tr><td>Photoshop drawing software</td><td>Adobe</td><td></td><td>Process images</td></tr><tr><td>SCIREQ INEXPOSE</td><td>EMKA Biotech Beijing Co.,Ltd.</td><td></td><td>Atomizing device</td></tr><tr><td>Upright fluorescence microscope</td><td>Olympus</td><td>BX53</td><td>Observe the slice</td></tr></tbody></table>

a mouse model of pulmonary fibrosis induced by nasal bleomycin nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Pulmonary fibrosis is characteristic of several human lung diseases that arise from various causes. Given that treatment options are fairly limited, mouse models continue to be an important tool for developing new anti-fibrotic strategies. In this study, intrapulmonary administration of bleomycin (BLM) is carried out by nasal nebulization to create a mouse model of pulmonary fibrosis that closely mimics clinical disease characteristics. C57BL/6 mice received BLM (7 U/mL, 30 min/day) by nasal nebulization for 3 consecutive days and were sacrificed on day 9, 16, or 23 to observe inflammatory and fibrotic changes in lung tissue. Nasal aerosolized BLM directly targeted the lungs, resulting in widespread and uniform lung inflammation and fibrosis. Thus, we successfully generated an experimental mouse model of typical human pulmonary fibrosis. This method could easily be used to study the effects of the administration of various nasal aerosols on lung pathophysiology and validate new anti-inflammatory and anti-fibrotic treatments.

Lung injury was induced by nebulized BLM, and the control animals were nebulized with the same volume of normal saline. The mice were nebulized once a day for 3 days, 30 min per day, using a BLM concentration of 7 U/mL. Mice were sacrificed on days 9, 16, and 23 after BLM administration for H&amp;E staining (Figure 2B). Diffused pneumonic lesions with loss of the normal alveolar architecture, septal thickening, enlarged alveoli, and increased infiltration of inflammatory cells into the interstitial and p...

Various animal models of pulmonary fibrosis have been established using bleomycin to clarify the pathogenesis of pulmonary fibrosis and find new drug targets. However, most pulmonary fibrosis models targeting lung tissue have uneven drug administration. Here, we propose a model of uniform pulmonary fibrosis induced by nasal bleomycin nebulization.

Pulmonary fibrosis is characteristic of several human lung diseases that arise from various causes. Given that treatment options are fairly limited, mouse ...

a-mouse-model-pulmonary-fibrosis-induced-nasal-bleomycin

Research

JoVE Journal

Biology

This article presents a rapid and simple method for administering bleomycin directly into the mouse trachea via intubation. Key advantages of this method are that it is highly reproducible, easy to master, and does not require specialized equipment or lengthy recovery times.

An Improved Method for Rapid Intubation of the Trachea in Mice

We describe a non-invasive multimodal imaging approach based on Micro-CT and fluorescence molecular tomography for longitudinal assessment of the mouse lung fibrosis model induced by double intratracheal instillation of bleomycin.

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Here we present an effective method to investigate the antifibrotic activity of intravenously infused human mesenchymal stromal cells obtained from the whole umbilical cord following the induction of lung injury by an endotracheal injection of bleomycin in C57BL/6 mice. This protocol can be easily extended to the preclinical testing of other therapeutics.

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Here, the method of inducing pulmonary arterial hypertension associated with pulmonary fibrosis (PF-PH) rat model by injecting bleomycin into the airway is introduced. We also provide a step-by-step approach to validate this animal model.

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

This protocol demonstrates the oropharyngeal aspiration technique for use in the bleomycin murine model of pulmonary fibrosis.

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

This protocol delineates a method for inducing pulmonary fibrosis in mice through repeated oropharyngeal administration of bleomycin, yielding pathological features closely resembling those of idiopathic pulmonary fibrosis.

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Here, we present a protocol to model pulmonary fibrosis in mice using aerosolized bleomycin delivered via the trachea. This optimized method enables uniform, quantitative, and precise delivery without surgical incision, enhancing the reproducibility and reliability of bleomycin-induced fibrosis.

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Orthotopic animal models of ovarian cancer replicate better human disease and therefore enhance our understanding of cancer progression and tumor response to therapy.  A mouse model receives an intrabursal injection of luciferase-expressing ovarian tumor cells.  Treatment is administered via oral gavage.  Tumor growth is monitored by in vivo imaging system.

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Generating induced pluripotent stem cell (iPSC) lines produces lines of differing developmental potential even when they pass standard tests for pluripotency. Here we describe a protocol to produce mice derived entirely from iPSCs, which defines the iPSC lines as possessing full pluripotency1.

Generation of Mice Derived from Induced Pluripotent Stem Cells

Repeated retro-orbital injections of cationic liposomes/siRNA/ITSN-1s complexes in mice, every 72 hours for 24 days, efficiently deliver the siRNA duplex to the mouse lung microvasculature reducing ITSN-1s mRNA and protein expression by 75%. This technique is highly reproducible in an animal model, has no adverse effects and avoids fatalities.

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Learn nasal nebulization of bleomycin to induce pulmonary fibrosis in mice with uniform drug distribution. This method enables study of disease mechanisms and therapeutic development.

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Explore More Videos